Kakegawa

Researchers are investigating the effects of starting finerenone treatment early during hospitalization for patients with acute heart failure who have a left ventricular ejection fraction of 40% or higher. This Phase 4, multicenter, randomized, double-blind, placebo-controlled trial aims to assess whether early use of finerenone can improve outcomes in this patient group. Participants are randomly assigned to receive either finerenone or a matching placebo tablet. The finerenone dosing depends on kidney function: patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m² or less start at 10 mg once daily, with a maximum dose of 20 mg once daily; those with eGFR above 60 mL/min/1.73 m² start at 20 mg once daily, with a maximum dose of 40 mg once daily. Treatment begins within 36 hours after hospital admission, with randomization occurring within 24 hours. During the study, participants will be monitored for up to 12 weeks to evaluate a combined outcome of death and worsening heart failure. Researchers will conduct assessments including physical exams, symptom evaluation, laboratory tests, and heart function measurements. Safety and adherence to treatment will be tracked throughout the study, ensuring comprehensive evaluation of the therapy's impact during the critical early phase of hospitalization.